4 results
Approved WMOCompleted
To investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.
Approved WMOCompleted
The current study is being conducted to determine whether long-term dual-antiplatelet therapy with ticagrelor in combination with ASA (recommended daily dose 75-100 mg) is beneficial in patients with history of MI (1-3 years ago) and additional risk…
Approved WMOCompleted
To evaluate safety of 3-months versus standard 12-months of DAPT
Approved WMOCompleted
To compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established peripheral artery disease.